Comparative Pharmacology
Head-to-head clinical analysis: FUZEON versus SYLATRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUZEON versus SYLATRON.
FUZEON vs SYLATRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
90 mg subcutaneously twice daily
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
None Documented
None Documented
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing.
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces.
Category C
Category C
Antiviral
Interferon Antineoplastic/Antiviral